Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
19:16:16 EST Sat 07 Feb 2026
Enter Symbol
or Name
USA
CA



Q:FATE - FATE THERAPEUTICS - https://www.fatetherapeutics.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
FATE - Q1.01.05·1.150.41.14+0.098.61,501.41,5454,1391.06  1.14  1.051.9399  0.661119:32:30Feb 0315 min RT 2¢

Recent Trades - Last 10 of 4139
Time ETExPriceChangeVolume
19:32:30Q1.150.1046
19:02:11Q1.140.0950
18:56:46Q1.140.0920
18:34:19Q1.13310.0831149
18:25:32Q1.130.082
18:19:40Q1.150.1020
16:10:04Q1.140.091
16:10:04Q1.140.091
16:05:04Q1.13010.080110
16:04:55Q1.140.091

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-02-03 16:05U:FATENews ReleaseFate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
2026-01-23 12:56U:FATENews ReleaseBreaking Barriers: How 2026's Top Clinical Leaders Are Disrupting Chronic Disease Markets
2026-01-05 16:05U:FATENews ReleaseFate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
2025-12-08 08:00U:FATENews ReleaseFate Therapeutics Presents Updated Phase 1 Clinical Data of FT819 Off-the-shelf CAR T-cell Product Candidate for Systemic Lupus Erythematosus and Preclinical Advances in Next-Generation Off-the-Shelf CAR T-cell Programs
2025-11-25 08:00U:FATENews ReleaseFate Therapeutics to Present at Piper Sandler 37th Annual Healthcare Conference
2025-11-13 08:30U:FATENews ReleaseFate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates
2025-11-04 16:01U:FATENews ReleaseFate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
2025-10-26 11:30U:FATENews ReleaseFate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients with Systemic Lupus Erythematosus Treated with FT819 Off-the-Shelf CAR T-Cell Therapy
2025-10-14 08:00U:FATENews ReleaseFate Therapeutics Expands Leadership Team with Appointment of Kamal Adawi as Chief Financial Officer
2025-10-02 16:01U:FATENews ReleaseFate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
2025-09-03 16:01U:FATENews ReleaseFate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
2025-08-25 08:00U:FATENews ReleaseFate Therapeutics to Present at Upcoming Investor Conferences
2025-08-12 16:01U:FATENews ReleaseFate Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates
2025-08-05 16:01U:FATENews ReleaseFate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
2025-07-03 13:05U:FATENews ReleaseFate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
2025-06-11 09:00U:FATENews ReleaseFate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission for Severe Lupus Nephritis at EULAR 2025 Congress
2025-05-30 16:30U:FATENews ReleaseFate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors
2025-05-28 17:54U:FATENews ReleaseFate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 Congress
2025-05-13 16:01U:FATENews ReleaseFate Therapeutics Reports First Quarter 2025 Financial Results and Business Updates
2025-05-02 16:01U:FATENews ReleaseFate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)